KBL Merger Corp. IV (NASDAQ: KBLM ) on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp. CannBioRx Life Sciences Corp. has three synergistic programs that ...

NEW YORK, July 26, 2019 /PRNewswire/ -- KBL Merger Corp. IV (KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC), announced today that it has executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with CannBioRx Life Sciences Corp. ("CannBioRx"), a drug development company focused on treating inflammatory diseases. The transaction is subject to the approval by KBLM's and CannBioRx's respective shareholders. There can be no assurance that the proposed transaction will be completed on the terms set forth in the definitive agreement, or at all.